Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9691788 | 0.87 | ALDH1A1 (0.34) | ALDH1A1HPGD | |
| SCHEMBL30601232 | 0.80 | ALDH1A1 (0.39) | ALDH1A1HPGDFFAR1CYP1A1CYP1A2 | |
| SCHEMBL954765 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDFFAR1MEN1KMT2A | |
| SCHEMBL31503923 | 0.75 | TSHR (0.41) | ALDH1A1TSHRCTSB | |
| SCHEMBL8358228 | 0.75 | CTSB (0.49) | TSHRMEN1MAPTKMT2ACTSB | |
| SCHEMBL28260280 | 0.75 | TSHR (0.41) | TSHR | |
| SCHEMBL7049394 | 0.75 | TSHR (0.41) | ALDH1A1TSHRCTSB | |
| SCHEMBL31325361 | 0.73 | TSHR (0.40) | ALDH1A1TSHRMEN1KMT2ACTSB | |
| SCHEMBL28283505 | 0.73 | CTSB (0.47) | TSHRMEN1MAPTKMT2ACTSB | |
| SCHEMBL1023433 | 0.73 | PTGDR2 (0.40) | ALDH1A1HPGDMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| EP-3329919-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885HPGD 872/4885TSHR 4633/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885HPGD 872/4885TSHR 4633/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885HPGD 872/4885TSHR 4633/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885HPGD 872/4885TSHR 4633/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885HPGD 872/4885TSHR 4633/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885HPGD 872/4885TSHR 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.